文献速递脑血管病

血管内治疗串联闭塞时抗血小板治疗的影响:协作汇总分析

Impact of Antiplatelet Therapy During Endovascular Therapy for Tandem Occlusions: A Collaborative Pooled Analysis.
PubMed 文献 · Stroke · 2020-03-19

该研究基于TITAN多中心登记中11个前瞻性数据库的回顾性汇总分析,纳入369例前循环串联闭塞接受血管内治疗的患者,按术中是否使用抗血小板药分组。结果显示抗血小板治疗与90天死亡率显著降低相关(11.2% vs 18.7%;aOR 0.47,95%CI 0.22-0.98;P=0.042),且未增加任何颅内出血风险,成功再灌注率显著更优(83.9% vs 71.0%;aOR 1.89,95%CI 1.01-3.64;P=0.045),但良好预后率差异无统计学意义(58.3% vs 46.0%;aOR 1.38,95%CI 0.78-2.43;P=0.26)。

要点

  • 前循环串联闭塞血管内治疗术中使用抗血小板药与90天死亡率显著降低相关。
  • 抗血小板治疗未增加任何颅内出血风险,成功再灌注率显著更优。
  • 良好预后率在抗血小板组数值更高但差异无统计学意义。

核心结论

  • 前循环串联闭塞血管内治疗期间给予抗血小板治疗是安全的,并与较低的90天死亡率相关。

研究设计与样本

  • 本研究为多中心观察性TITAN登记(Thrombectomy in Tandem Lesions)中11个前瞻性数据库的协作汇总回顾性分析。
  • 共纳入369例患者,按血管内治疗术中抗血小板药物使用数量分组,145例(39.3%)未接受任何抗血小板药,224例(60.7%)接受至少1种抗血小板药。

主要发现

  • 抗血小板治疗组良好预后(90天mRS 0-2)率为58.3%,未抗血小板组为46.0%,差异无统计学意义(aOR 1.38,95%CI 0.78-2.43;P=0.26)。
  • 抗血小板治疗组90天死亡率为11.2%,显著低于未抗血小板组的18.7%(aOR 0.47,95%CI 0.22-0.98;P=0.042)。
  • 抗血小板治疗组成功再灌注(mTICI 2b-3)率为83.9%,显著优于未抗血小板组的71.0%(aOR 1.89,95%CI 1.01-3.64;P=0.045)。
  • 抗血小板治疗未增加任何颅内出血风险。

关键数值与推荐

  • 良好预后定义为90天改良Rankin量表(mRS)评分0-2分。
  • 成功再灌注定义为改良脑缺血溶栓评分(mTICI)2b-3级。

临床怎么用

  • 前循环串联闭塞血管内治疗术中使用抗血小板药可能降低90天死亡率并提高成功再灌注率,且不增加颅内出血风险。
  • 最佳抗血小板治疗方案尚待评估,尤其在急诊颈动脉支架置入时。

局限性

  • 本研究为回顾性汇总分析,非随机对照设计。
  • 最佳抗血小板治疗策略尚未确定,需进一步随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Antiplatelet agents could be used in the setting of endovascular therapy for tandem occlusions to reduce the risk of de novo intracranial embolic migration, reocclusion of the extracranial internal carotid artery lesion, or in-stent thrombosis in case of carotid stent placement but have to be balanced with the intracerebral hemorrhagic transformation risk. In this study, we aim to investigate the impact of acute antiplatelet therapy administration on outcomes during endovascular therapy for anterior circulation tandem occlusions. Methods- This is a retrospective analysis of a collaborative pooled analysis of 11 prospective databases from the multicenter observational TITAN registry (Thrombectomy in Tandem Lesions). Patients were divided into groups based on the number of antiplatelet administered during endovascular therapy. The primary outcome was favorable outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days. Results- This study included a total of 369 patients; 145 (39.3%) did not receive any antiplatelet agent and 224 (60.7%) received at least 1 antiplatelet agent during the procedure. Rate of favorable outcome was nonsignificantly higher in patients treated with antiplatelet therapy (58.3%) compared with those treated without antiplatelet (46.0%; adjusted odds ratio, 1.38 [95% CI, 0.78-2.43]; P=0.26). Rate of 90-day mortality was significantly lower in patients treated with antiplatelet therapy (11.2% versus 18.7%; adjusted odds ratio, 0.47 [95% CI, 0.22-0.98]; P=0.042), without increasing the risk of any intracerebral hemorrhage. Successful reperfusion (modified Thrombolysis in Cerebral Ischemia score 2b-3) rate was significantly better in the antiplatelet therapy group (83.9% versus 71.0%; adjusted odds ratio, 1.89 [95% CI, 1.01-3.64]; P=0.045). Conclusions- Administration of antiplatelet therapy during endovascular therapy for anterior circulation tandem occlusions was safe and was associated with a lower 90-day mortality. Optimal antiplatelet therapy remains to be assessed, especially when emergent carotid artery stenting is performed. Further randomized controlled trials are needed.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhu F, Anadani M, Labreuche J, et al. Impact of Antiplatelet Therapy During Endovascular Therapy for Tandem Occlusions: A Collaborative Pooled Analysis. Stroke. 2020. PMID: 32188367. doi:10.1161/STROKEAHA.119.028231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。